Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Alnylam Pharmaceuticals's selling, general, & admin. expense for the
three
months ended in Mar. 2026 was $323 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $1,293 Mil.
Alnylam Pharmaceuticals (LTS:0HD2) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Alnylam Pharmaceuticals Selling, General, & Admin. Expense Related Terms
Alnylam Pharmaceuticals Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Alnylam Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Selling, General, & Admin. Expense Chart
LTS:0HD2 vs ONC, RVMD, RPRX: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Selling, General, & Admin. Expense falls into.
Alnylam Pharmaceuticals Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,293 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $1,293 Mil mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Selling, General, & Admin. Expense of $1,293 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Selling, General, & Admin. Expense too high?
Alnylam Pharmaceuticals' current Selling, General, & Admin. Expense is $1,293 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Selling, General, & Admin. Expense compare to ONC and RVMD?
Alnylam Pharmaceuticals' Selling, General, & Admin. Expense of $1,293 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Selling, General, & Admin. Expense is $1,293 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $535.69, compared to a current price of $281.76 — trading 47.4% below its estimated fair value. The current Selling, General, & Admin. Expense is $1,293 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Selling, General, & Admin. Expense is $1,293 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $281.76 is trading 47.4% below its estimated GF Value™ of $535.69.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Selling, General, & Admin. Expense: $1,293 Mil
GF Value™: $535.69 vs. price of $281.76 (47.4% below fair value)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
62GF Score
Get the complete analysis for LTS:0HD2
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
